Lim, S. H., Choi, Y.-L., Jung, S.-H., Ahn, M.-J., Park, K., Zo, J. I., … Sun, J.-M. (2016). A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma. In Annals of Oncology (Vol. 27, pp. vi218–vi218). Elsevier BV. https://doi.org/10.1093/annonc/mdw371.35

Lim, S. H., Y. -. L. Choi, S. -. H. Jung, M. -. J. A. Ahn, K. Park, J. I. Zo, Y. M. Shim, and J. -. M. Sun. “A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma.” In Annals of Oncology, 27:vi218–vi218. Elsevier BV, 2016. https://doi.org/10.1093/annonc/mdw371.35.

Lim SH, Choi Y-L, Jung S-H, Ahn M-JA, Park K, Zo JI, et al. A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma. In: Annals of Oncology. Elsevier BV; 2016. p. vi218–vi218.

Lim, S. H., et al. “A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma.” Annals of Oncology, vol. 27, Elsevier BV, 2016, pp. vi218–vi218. Crossref, doi:10.1093/annonc/mdw371.35.

Lim SH, Choi Y-L, Jung S-H, Ahn M-JA, Park K, Zo JI, Shim YM, Sun J-M. A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma. Annals of Oncology. Elsevier BV; 2016. p. vi218–vi218.